Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 6/20 | 0.38 |
| ▸ | RARG | P13631 | 6/20 | 0.38 |
| ▸ | RARA | P10276 | 5/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8732926 | 0.90 | RXRA (0.40) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL9419032 | 0.88 | RXRA (0.38) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL31003100 | 0.88 | RXRA (0.40) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL9419052 | 0.87 | UGT2B7 (0.35) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL9770517 | 0.85 | HPGD (0.41) | RXRARXRBCYP3A4HTR2AHTR2C | |
| SCHEMBL3541162 | 0.81 | RXRA (0.58) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL9770709 | 0.79 | ALDH1A1 (0.40) | RXRARXRBCYP26A1CYP3A4CYP26B1 | |
| SCHEMBL9418950 | 0.79 | RXRA (0.51) | RXRARXRBUGT2B7RARBRARG | |
| SCHEMBL29743366 | 0.78 | RXRA (0.38) | RXRARXRBRARBRARGRARA | |
| Isopropylbenzene SCHEMBL11245662 | 0.78 | RXRA (0.38) | RXRARXRBCYP3A4KARS1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | RXRA 101/4885RXRB 57/4885UGT2B7 214/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | RXRA 446/4885RXRB 457/4885UGT2B7 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.